KOR

e-Article

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial
Document Type
Article
Author
Ajana, FArribas, JRBailey, JBenson, PBerenguer, JBhatti, LBlaxhult, ABrar, IBredeek, UFBrinson, CBrunetta, JCasado, JClarke, AConway, BCotte, LCrofoot, GCunningham, Dde Vente, JDe Wit, SDeJesus, EDietz, CDretler, REron, JFehr, JFelizarta, FFichtenbaum, CFlamholc, LFlorence, EGalindo, MJGallant, JGasiorowski, JGatell, JMGathe, JGazzard, BGGirard, P-MGisslèn, MGutierrez, FGutierrez, MDMHagins, DHalota, WHenn, SHenry, WKHorban, AHuhn, GIribarren, JAJain, MJohnson, MAKatlama, CKlein, MKnobel, HLucasti, CMartorell, CMcDonald, CMills, AMolina, J-MMorales-Ramirez, JMounzer, KMoutschen, MMurphy, DNahass, RNegredo, EOlivet, HOrkin, COsiyemi, OPerez-Valero, IPiekarska, APineda, JAPodzamczer, DPoizot-Martin, IPortilla Sogorb, JPost, FPrelutsky, DPulido, FRachlis, ARaffi, FRamgopal, MRashbaum, BRauch, ARey, DReynes, JRicart, CRichmond, GRivero, ARuane, PGil, I SantosScarsella, AScribner, AShafran, SShalit, PShamblaw, DSlim, JStoeckle, MTashima, KTeicher, EThalme, AUstianowski, AVan Wijngaerden, EVandekerckhove, LVandercam, BVoskuhl, GWalmsley, SWard, DWaters, LWilkin, AWitor, AYazdanpanah, YOrkin, ChloeMolina, Jean-MichelNegredo, EugeniaArribas, José RGathe, JosephEron, Joseph JVan Landuyt, ErikaLathouwers, ErkkiHufkens, VeerlePetrovic, RomanaVanveggel, SimonOpsomer, Magda
Source
In The Lancet HIV January 2018 5(1):e23-e34
Subject
Primary Research
Articles
Language
ISSN
2352-3018